IL17A and systemic lupus erythematosus: In addition, lupus IgG1, but not control IgG1, increased serum C3 and complement factors B levels (Supplemental Figure 3B), decreased serum IFN-γ and IL-17 levels (Supplemental Figure 3C), as well as decreased serum creatinine and BUN levels (Supplemental Figure 3D) in MRL-lpr/lpr mice by a dose-dependent manner within a range of 0.5 mg to 3.0 mg per mouse in vivo.